New product launches helped GlaxoSmithKline Pharmaceuticals (GSK), the Indian arm of the world’s second largest drug maker, post a 6.9 per cent increase in net profit to Rs 141 crore for the quarter ended September, against Rs 132 crore in the same quarter last year.
Net sales of GSK India were up 12 per cent during the quarter, at Rs 511.8 crore against Rs 457 crore in the same period last year.
“Recent launches of Tykerb for breast cancer, anti-hypertensive drug Benitec from Daiichi Sankyo and Cervarix for cervical cancer are making steady progress. Vaccines have recorded strong growth too,” MD Hasit B Joshipura said.
